Cargando…
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
Immunooncology is still a growing area in cancer therapy. Drugs within this therapeutic approach do not directly target/attack the tumor but interfere with immune checkpoints and target or reprogram key metabolic pathways critical for anti-cancer immune defense. Indolamine 2,3-dioxygenase 1 (IDO1) a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682646/ https://www.ncbi.nlm.nih.gov/pubmed/31417567 http://dx.doi.org/10.3389/fimmu.2019.01801 |